Pradaxa Cases Filed
Eight cases have been filed by individuals for personal injuries against Defendants Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Corporation, Boehringer Ingelheim USA Corporation, and Boehringer Ingelheim Vetmedica, Inc., the manufacturers of Pradaxa.
Pradaxa is a direct thrombin inhibitor that is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The complaints allege there is an increased risk in severe bleeding for users of Pradaxa compared to Warfarin.
Boehringer Ingelheim Corporation marketed Pradaxa® as being more effective than Warfarin in preventing stroke and systemic embolism, providing a convenient alternative to Warfarin therapy because it does not require blood monitoring or dose adjustments, and does not require any dietary restrictions. The complaints also allege the Defendants failed to warn emergency room doctors, surgeons and other critical care medical professionals that unlike generally-known measures taken to treat and stabilize bleeding in users of warfarin, there is no effective agent to reverse the anticoagulation effects of Pradaxa, and therefore no effective means to treat and stabilize patients who experience uncontrolled bleeding while taking Pradaxa.
Attorneys at Schlichter Bogard and Denton, LLP, are investigating claims associated with Pradaxa for individuals who have experienced brain hemorrhage, severe bleeding, and for families who have lost a loved one after taking Pradaxa. If you or someone you know has been injured by Pradaxa please contact the product liability lawyers of Schlichter Bogard & Denton today to discuss your case.